Amit Kumar Halder


AuthID: R-00J-AZS

Confirmed Publications: 73



41
TITLE: Inhibition of Mycobacterium tuberculosis L,D-Transpeptidase 5 by Carbapenems: MD and QM/MM Mechanistic Studies
AUTHORS: Gideon F Tolufashe; Amit K Halder ; Collins U Ibeji; Monsurat M Lawal; Thandokuhle Ntombela; Thavendran Govender; Glenn E M Maguire; Gyanu Lamichhane; Hendrik G Kruger; Bahareh Honarparvar;
PUBLISHED: 2018, SOURCE: ChemistrySelect, VOLUME: 3, ISSUE: 48
INDEXED IN: CrossRef: 6
IN MY: ORCID
42
TITLE: QSAR modelling: a therapeutic patent review 2010-present
AUTHORS: Amit Kumar Halder ; Ana S Moura ; Natalia N D S Cordeiro ;
PUBLISHED: 2018, SOURCE: EXPERT OPINION ON THERAPEUTIC PATENTS, VOLUME: 28, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef: 28
IN MY: ORCID
43
TITLE: Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches  Full Text
AUTHORS: Halder, AK ; Amin, SA; Jha, T; Gayen, S;
PUBLISHED: 2017, SOURCE: SAR and QSAR in Environmental Research, VOLUME: 28, ISSUE: 3
INDEXED IN: Scopus CrossRef: 24
IN MY: ORCID
44
TITLE: Possible anticancer agents: synthesis, pharmacological activity, and molecular modeling studies on some 5-N -Substituted-2-N-(substituted benzenesulphonyl)-L(+)Glutamines  Full Text
AUTHORS: Jha, T; Basu, S; Halder, AK ; Adhikari, N; Samanta, S;
PUBLISHED: 2017, SOURCE: Medicinal Chemistry Research, VOLUME: 26, ISSUE: 7
INDEXED IN: Scopus CrossRef: 1
IN MY: ORCID
45
TITLE: Ligand- and structure- based drug design of non- steroidal aromatase inhibitors (NSAIs) in breast cancer
AUTHORS: Jha, T; Halder, AK ; Adhikari, N; Saha, A;
PUBLISHED: 2016, SOURCE: Oncology: Breakthroughs in Research and Practice, VOLUME: 1-2
INDEXED IN: Scopus CrossRef: 1
IN MY: ORCID
46
TITLE: Nitric oxide synthase (NOS) inhibitors in cancer angiogenesis
AUTHORS: Halder, AK ; Mukherjee, A; Adhikari, N; Saha, A; Jha, T;
PUBLISHED: 2016, SOURCE: Current Enzyme Inhibition, VOLUME: 12, ISSUE: 1
INDEXED IN: Scopus
IN MY: ORCID
47
TITLE: Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays  Full Text
AUTHORS: Adhikari, N; Halder, AK ; Mallick, S; Saha, A; Saha, KD; Jha, T;
PUBLISHED: 2016, SOURCE: Bioorganic and Medicinal Chemistry, VOLUME: 24, ISSUE: 18
INDEXED IN: Scopus CrossRef: 53
IN MY: ORCID
48
TITLE: Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents  Full Text
AUTHORS: Mondal, C; Halder, AK ; Adhikari, N; Saha, A; Saha, KD; Gayen, S; Jha, T;
PUBLISHED: 2015, SOURCE: European Journal of Medicinal Chemistry, VOLUME: 90
INDEXED IN: Scopus CrossRef: 23
IN MY: ORCID
49
TITLE: Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity
AUTHORS: Halder, AK ; Mallick, S; Shikha, D; Saha, A; Saha, KD; Jha, T;
PUBLISHED: 2015, SOURCE: RSC Advances, VOLUME: 5, ISSUE: 88
INDEXED IN: Scopus CrossRef: 64
IN MY: ORCID
50
TITLE: Ligand-and structure-based drug design of non-steroidal aromatase inhibitors (NSAIs) in breast cancer
AUTHORS: Jha, T; Adhikari, N; Halder, AK ; Saha, A;
PUBLISHED: 2015, SOURCE: Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment
INDEXED IN: Scopus CrossRef: 5
IN MY: ORCID
Page 5 of 8. Total results: 73.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service